We found that higher expression of three biomarkers was significantly associated with poorer overall survival, relapse-free survival, post-progression survival, and disease-specific survival, suggesting that YWHAB, PPAT, and NOL10 were reliable biomarkers for HCC prognosis (Figures 9A–C). This evidence concerns the gene PPAT and hepatocellular carcinoma.